생물정신의학 (Korean Journal of Biological Psychiatry)

  • 제19권1호
  • /
  • Pages.60-64
  • /
  • 2012
  • /
  • 1225-8709(pISSN)
  • /
  • 2005-7571(eISSN)
대한생물정신의학회 (The Korean Society of Biological Psychiatry)
권호 표지

한국인 조현병 환자와 도파민 D2 수용체 유전자 다형성과의 관련연구

Association Study between DRD2 Genetic Polymorphisms and Schizophrenia in a Korean Population

  • 김태성 (충남대학병원 정신건강의학과) ;
  • 차승민 (충남대학병원 정신건강의학과) ;
  • 왕성근 (충남대학교 의학전문대학원 정신건강의학교실) ;
  • 김정란 (충남대학교 의학전문대학원 정신건강의학교실) ;
  • 이영호 (충남대학교 의학전문대학원 해부학교실) ;
  • 최혜인 (충남대학교 의학전문대학원 해부학교실) ;
  • 지익성 (충남대학교 의학전문대학원 정신건강의학교실)
  • Kim, Tae-Sung (Department of Psychiatry, Chungnam National University Hospital) ;
  • Cha, Seung-Min (Department of Psychiatry, Chungnam National University Hospital) ;
  • Wang, Seong-Keun (Department of Psychiatry, School of Medicine, Chungnam National University) ;
  • Kim, Jeong-Lan (Department of Psychiatry, School of Medicine, Chungnam National University) ;
  • Lee, Young-Ho (Department of Anatomy, School of Medicine, Chungnam National University) ;
  • Choi, Hye-In (Department of Anatomy, School of Medicine, Chungnam National University) ;
  • Chee, Ik-Seung (Department of Psychiatry, School of Medicine, Chungnam National University)
  • 투고 : 2011.08.19
  • 심사 : 2011.09.20
  • 발행 : 2012.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : This study was designed to investigate the association between the dopamine D2 receptor (DRD2) genetic polymorphism [TaqIB (rs17294542) and TaqID (rs1800498)] and patients with schizophrenia. Methods : TaqIB (rs17294542) and TaqID (rs1800498) polymorphism of the DRD2 gene were typed in 100 patients with schizophrenia and 109 normal controls. Results : There were no statistical differences in genotype and allele distribution of TaqIB (rs17294542) and TaqID (rs1800498) genetic polymorphism between patients with schizophrenia and normal controls. Conclusions : These results suggest that the TaqIB (rs17294542) and TaqID (rs1800498) polymorphisms of the DRD2 gene may not be associated with schizophrenia in the Korean population.

키워드

참고문헌

  1. Serretti A, Mandelli L, Bajo E, Cevenini N, Papili P, Mori E, et al. The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. Eur Psychiatry 2009;24:11-16 https://doi.org/10.1016/j.eurpsy.2008.07.009
  2. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet 1995;346:678-682. https://doi.org/10.1016/S0140-6736(95)92285-7
  3. Tsuang MT, Gilbertson MW, Faraone SV. The genetics of schizophrenia. Current knowledge and future directions. Schizophr Res 1991;4:157-171. https://doi.org/10.1016/0920-9964(91)90031-L
  4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186. https://doi.org/10.1016/0893-133X(88)90012-7
  5. Sobell JL, Heston LL, Sommer SS. Novel association approach for determining the genetic predisposition to schizophrenia: case-control resource and testing of a candidate gene. Am J Med Genet 1993;48:28-35. https://doi.org/10.1002/ajmg.1320480108
  6. Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991;266:1793-1800. https://doi.org/10.1001/jama.1991.03470130073032
  7. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-1090. https://doi.org/10.1016/j.pnpbp.2003.09.004
  8. Dubertret C, Bardel C, Ramoz N, Martin PM, Deybach JC, Ades J, et al. A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:492-499. https://doi.org/10.1016/j.pnpbp.2010.02.003
  9. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989;45:778-785.
  10. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991;10:527-530. https://doi.org/10.1016/0888-7543(91)90431-D
  11. Parsian A, Fisher L, O'Malley KL, Todd RD. A new TaqI RFLP within intron 2 of human dopamine D2 receptor gene (DRD2). Nucleic Acids Res 1991;19:6977.
  12. Lee HS, Lee MS, Suh KY. Distribution of the TaqI polymorphism of the dopamine D2 receptor in a Korean schizophrenic population. J Korean Neuropsychiatric Assoc 1995;34:1641-1651.
  13. Kang CJ. The relationship between Taq I A dopamine D2 receptor polymorphism and therapeutic response to antipsychotics in schizophrenic patients. Korean J Biological Psychiatry 2005;12:107-113.
  14. Lee SI, Cho IH, Kim SM, Lee MS, Jung HY. Association study between tic disorder and dopamine D2 receptor gene polymorphism in Korean population. Korean J Biological Psychiatry 2006;13:299-304.
  15. Choi TY, Kim HN, Han DH, Min KJ, Lee YS, Na C. Relationship between alcohol withdrawal symptoms and dopaminergic gene polymorphisms (DRD2, DAT, COMT) in alcohol dependence patients. Korean J Biological Psychiatry 2006;13:178-189.
  16. Lim SW, Kim BJ, Oh KS, Lee MS. Association between panic disorder and dopamine D2 receptor TaqI A polymorphism. Anxiety and Mood 2006;2:45-49.
  17. Kim BJ, Lim SW, Shin DW, Oh KS, Lee MS. Dopamine D2 receptor gene TaqI A polymorphism in Korean social phobia patients: preliminary study. Korean J of Biological Psychiatry 2007;14:106-114.
  18. Lee SY, Chung HG, Kim TY, Choi JH, Chung MY, So HS, et al. D2 dopamine receptor (DRD2) gene polymorphism and combat-related posttraumatic stress disorder in vietnam veterans. Anxiety and Mood 2008;4:142-147.
  19. Castiglione CM, Deinard AS, Speed WC, Sirugo G, Rosenbaum HC, Zhang Y, et al. Evolution of haplotypes at the DRD2 locus. Am J Hum Genet 1995;57:1445-1456.
  20. Kidd KK, Pakstis AJ, Castiglione CM, Kidd JR, Speed WC, Goldman D, et al. DRD2 haplotypes containing the TaqI A1 allele: implications for alcoholism research. Alcohol Clin Exp Res 1996;20:697-705. https://doi.org/10.1111/j.1530-0277.1996.tb01674.x
  21. Dubertret C, Gorwood P, Gouya L, Deybach JC, Ades J. Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. Schizophr Res 2001;49:203-212. https://doi.org/10.1016/S0920-9964(00)00085-2
  22. Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, et al. The 3' region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res 2004;67:75-85. https://doi.org/10.1016/S0920-9964(03)00220-2
  23. Golimbet VE, Aksenova MG, Nosikov VV, Orlova VA, Kaleda VG. Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 2003;33:223-225. https://doi.org/10.1023/A:1022191012698
  24. Behravan J, Hemayatkar M, Toufani H, Abdollahian E. Linkage and association of DRD2 gene TaqI polymorphism with schizophrenia in an Iranian population. Arch Iran Med 2008;11:252-256.
  25. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/ intolerant populations. Psychopharmacology (Berl) 2005;181:179-187. https://doi.org/10.1007/s00213-005-2223-5
  26. Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007;3:34. https://doi.org/10.1186/1744-9081-3-34
  27. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002;7:695-705. https://doi.org/10.1038/sj.mp.4001054
  28. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 2006;27:966-970. https://doi.org/10.1111/j.1745-7254.2006.00355.x
  29. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007;10:631-637.
  30. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008;161:131-141. https://doi.org/10.1016/j.psychres.2007.08.002
  31. Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No evidence for an association between dopamine D2 Receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011;8:49-54. https://doi.org/10.4306/pi.2011.8.1.49
  32. Lee KY, Joo EJ, Ji YI, Kim DH, Park JB, Chung IW, et al. Associations between DRDs and schizophrenia in a Korean population: multistage association analyses. Exp Mol Med 2011;43:44-52. https://doi.org/10.3858/emm.2011.43.1.005